142 related articles for article (PubMed ID: 9333574)
1. Case-control study to evaluate the efficacy of the BIKEN acellular pertussis vaccine combined with diphtheria and tetanus toxoids (DTaP) in infants.
Beloradsky BH
Dev Biol Stand; 1997; 89():70-3. PubMed ID: 9333574
[No Abstract] [Full Text] [Related]
2. A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine.
Stehr K; Cherry JD
Dev Biol Stand; 1997; 89():58-62. PubMed ID: 9333571
[No Abstract] [Full Text] [Related]
3. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
[TBL] [Abstract][Full Text] [Related]
4. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection.
Heininger U; Stehr K; Christenson P; Cherry JD
Clin Infect Dis; 1999 Mar; 28(3):602-4. PubMed ID: 10194085
[TBL] [Abstract][Full Text] [Related]
5. Efficacy trial of acellular pertussis vaccines; trial I.
Olin P
Dev Biol Stand; 1997; 89():52-4. PubMed ID: 9333569
[No Abstract] [Full Text] [Related]
6. Efficacy of a three-component acellular pertussis vaccine (DTaP) in early childhood after household exposure to "typical" (WHO-defined) pertussis.
Schmitt HJ
Dev Biol Stand; 1997; 89():67-9. PubMed ID: 9333573
[No Abstract] [Full Text] [Related]
7. The Gothenburg pertussis vaccine study.
Trollfors B; Taranger J
Dev Biol Stand; 1997; 89():49-51. PubMed ID: 9333568
[No Abstract] [Full Text] [Related]
8. Sénégal pertussis trial.
Simondon F
Dev Biol Stand; 1997; 89():63-6. PubMed ID: 9333572
[No Abstract] [Full Text] [Related]
9. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
[TBL] [Abstract][Full Text] [Related]
10. The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins.
Robbins JB; Schneerson R; Trollfors B; Sato H; Sato Y; Rappuoli R; Keith JM
J Infect Dis; 2005 Jan; 191(1):81-8. PubMed ID: 15593007
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of an acellular pertussis vaccine in Japanese children during a non-epidemic period: a matched case-control study.
Okada K; Ohashi Y; Matsuo F; Uno S; Soh M; Nishima S
Epidemiol Infect; 2009 Jan; 137(1):124-30. PubMed ID: 18474125
[TBL] [Abstract][Full Text] [Related]
12. Implications of different study designs for the evaluation of acellular pertussis vaccines.
Fine PE
Dev Biol Stand; 1997; 89():123-33. PubMed ID: 9272342
[TBL] [Abstract][Full Text] [Related]
13. Pertussis vaccine trials. Trial synopses.
Dev Biol Stand; 1997; 89():37-47. PubMed ID: 9333567
[No Abstract] [Full Text] [Related]
14. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
America Academy of Pediatrics Commitee on Infectious Diseases
Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
[TBL] [Abstract][Full Text] [Related]
15. Safety of acellular pertussis vaccine: follow-up studies.
Chen RT
Dev Biol Stand; 1997; 89():373-5. PubMed ID: 9272374
[No Abstract] [Full Text] [Related]
16. The effectiveness of whole-cell pertussis vaccines.
Plotkin SA
Dev Biol Stand; 1997; 89():171-4. PubMed ID: 9272348
[TBL] [Abstract][Full Text] [Related]
17. Magnitude of interference after diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b capsular polysaccharide-tetanus vaccination is related to the number of doses administered.
Daum RS; Zenko CE; Given GZ; Ballanco GA; Parikh H; Germino K
J Infect Dis; 2001 Nov; 184(10):1293-9. PubMed ID: 11679918
[TBL] [Abstract][Full Text] [Related]
18. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules.
Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C
Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838
[TBL] [Abstract][Full Text] [Related]
19. Comparative Efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group.
Heininger U; Cherry JD; Stehr K; Schmitt-Grohé S; Uberall M; Laussucq S; Eckhardt T; Meyer M; Gornbein J
Pediatrics; 1998 Sep; 102(3 Pt 1):546-53. PubMed ID: 9738175
[TBL] [Abstract][Full Text] [Related]
20. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
